HighTower Advisors’s Redhill Biopharma RDHL Stock Holding History

HighTower Advisors’s Portfolio RDHL Stock Details RDHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-12	Closed	-$32K	–	3639
2021 Q4	$32K	Buy	+12	New	+$48K	﹤0.01%	3066

Other funds holding RDHL

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Claret Asset Management Montreal, Quebec, Canada $837M AUM 25.51% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

HighTower Advisors's RDHL Position: Q1 2022 in Review

HighTower Advisors sold out of Redhill Biopharma (RDHL) in Q1 2022, closing a stake of 12 shares — an estimated $32K sold.

HighTower Advisors first reported a position in RDHL in Q4 2021 and held it in 1 quarter. The position peaked at $32K in Q4 2021. 43 funds tracked by Wall St. Rank hold RDHL as of Q1 2022.

HighTower Advisors reported no remaining Redhill Biopharma position as of Q1 2022 after selling out during the quarter.
HighTower Advisors sold 12 Redhill Biopharma shares in Q1 2022, an estimated $32K.
HighTower Advisors first reported a position in Redhill Biopharma in Q4 2021 and held it in 1 quarter.
HighTower Advisors's Redhill Biopharma position peaked at $32K in Q4 2021.
43 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2022.

Based on HighTower Advisors's 13F filing for Q1 2022, filed 12 May 2022.